Cargando…
DYRK1A antagonists rescue degeneration and behavioural deficits of in vivo models based on amyloid-β, Tau and DYRK1A neurotoxicity
Alzheimer’s disease (AD) involves pathological processing of amyloid precursor protein (APP) into amyloid-β and microtubule associated protein Tau (MAPT) into hyperphosphorylated Tau tangles leading to neurodegeneration. Only 5% of AD cases are familial making it difficult to predict who will develo...
Autores principales: | Zhu, Bangfu, Parsons, Tom, Foley, Christopher, Shaw, Yeng, Dunckley, Travis, Hulme, Christopher, Hodge, James J. L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508268/ https://www.ncbi.nlm.nih.gov/pubmed/36151233 http://dx.doi.org/10.1038/s41598-022-19967-y |
Ejemplares similares
-
The Omnipresence of DYRK1A in Human Diseases
por: Deboever, Estelle, et al.
Publicado: (2022) -
Dyrk1 inhibition improves Alzheimer's disease‐like pathology
por: Branca, Caterina, et al.
Publicado: (2017) -
DYRK1a Inhibitor Mediated Rescue of Drosophila Models of Alzheimer’s Disease-Down Syndrome Phenotypes
por: Zhu, Bangfu, et al.
Publicado: (2022) -
β-Carboline Compounds, Including Harmine, Inhibit DYRK1A and Tau Phosphorylation at Multiple Alzheimer's Disease-Related Sites
por: Frost, Danielle, et al.
Publicado: (2011) -
DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B
por: Yousefelahiyeh, Mina, et al.
Publicado: (2018)